



Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	1	Application Number	10/734,570
				Filing Date	December 12, 2003
				First Named Inventor	Rustum et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	03551.0145

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MG	1	KONOREV et al., <i>Cell-Permeable Superoxide Dismutase and Glutathione Peroxidase Mimetics Afford Superior Protection Against Doxorubicin-Induced Cardiotoxicity: The Role of Reactive Oxygen and Nitrogen Intermediates</i> , Archives Biochem. Biophysics, 1999, 368 (2) pp. 421-428, abstract.	
MG	2	KORBAC et al., <i>Doxorubicin Toxicity to the Skin: Possibility of Protection with Antioxidants Enriched Yeast</i> , J. Dermat. Sci., 2001, 25 (1) pp. 45-52, abstract.	
MG	3	CHEN et al., <i>Protective Effects of Selenium Supplementation in Minimizing 5-Fluorouracil Induced Lipid Peroxidative Damage of the Small Intestine</i> , J. Trace Elements in Experimental Med., 1997, 10 (3) pp. 163-171, abstract.	

Examiner Signature	<i>M. Jaffer</i>	Date Considered	7/1/05
--------------------	------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.